Community/Retail

The FDA is continuing to test ranitidine products from multiple manufacturers following the discovery of impurities in low levels in some medicines, including Zantac.

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

A recent phase 2 clinical trial found MicuRx Pharmaceuticals’ contezolid acefosamil (MRX-4) to be effective in treating acute bacterial skin and skin structure infections (ABSSSI) with dosing regimens that appeared to be safe and well-tolerated.

David Pope, PharmD, CDE, chief innovation officer at OmniSYS, and John King, CEO of OmniSYS, discuss how they use data to identify companion vaccines at the point-of-care.